Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages

  Béné, Johana ^a   Saïd, Worighi ^a   Rannou, Marianne ^a   Deheul, Sylvie ^a   Coupe, Patrick ^b   Gautier, Sophie ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Valenciennes Hospital Center   (France)

Author keywords

Adverse drug reaction; Dabigatran etexilate; Hemorrhagic disorders; International normalized ratio

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIVITAMIN K; BISOPROLOL; BUMETANIDE; CREATININE; CYPROTERONE; DABIGATRAN ETEXILATE; FLUINDIONE; FRESH FROZEN PLASMA; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; PERINDOPRIL; RIVASTIGMINE; ROSUVASTATIN; UREA; VITAMIN K GROUP; ZOPICLONE;

ACUTE KIDNEY FAILURE; AGED; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANEMIA; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CASE REPORT; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEHYDRATION; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTHROMBIN TIME; RECTUM HEMORRHAGE; THROMBOCYTE COUNT; TREATMENT DURATION; UREA BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; FEMALE; HEMORRHAGE; HEMOSTATIC DISORDERS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PYRIDINES; RECTAL DISEASES;

EID: 84862243930     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q705     Document Type: Article

References (12)

1. Boehringer Ingelheim. Pradaxa (dabigatran etexilate): advisory committee briefing document. August 27, 2010. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm226009.pdf (accessed 2012 Jan 2).
2. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885-9.
3. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-6.
4. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.
5. FDA Drug Safety Communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). December 7, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm282724.htm#sa (accessed 2012 Jan 2).
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol 2011;7:281-7.
8. Lecompte T, Toussaint-Hacquard M, Devignes J. Anticoagulant drugs: direct thrombin inhibitors. Ann Fr Anesth Reanim 2009;28:S3-7.
9. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
10. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010;49:259-68.
11. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-27.
12. Erenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.